Both patients with diabetes and health care professionals expect wider adoption of continuous glucose management systems in the future for patients with type 2 as well as type 1, and agree that cost is a key factor in patient choicesRead More »
New technology allows freedom from daily manual injections and oral antidiabetics.Read More »
Guest Post by David Kliff, Editor, Diabetic Investor
As I left Vienna after attending the 11th International Conference on Advanced Technologies & Treatments for Diabetes, my thoughts turned to what does this all mean, what was the most significant takeaway? By far the most significant development coming out of ATTD is the long quest to have a REAL closed-loop insulin delivery system is no longer a pipe dream. This is going to happen and for once I believe it will happen in my lifetime. It is difficult to overstate the power of the data I witnessed. The reality here is that some very smart people have come a very long way.
Young man, 21 years of age. type 1 diabetes since 9 years of age. Has not been to see hcp for a year. States he doesn’t like people interrogating him, but came in because he needs his insulin. States he doesn’t check his glucose because he can tell what it is. Tired of having type 1 diabetes and tired of checking numbers. A1C in office--10.2%.Read More »
By Guest Writer David Kliff, Publisher, Diabetic Investor
As 2018 begins, my attention turns toward a look back at the year gone by and ahead to the year that’s starting. As always, my New Year will begin in that beautiful city by the bay at the JP Morgan Healthcare Conference. This is a conference I suspect will be one of the more interesting, and since I’ve attended nearly 20, that’s saying something. Lots is going on behind the scenes in our wacky world, and given the nature of JPM I suspect the veil of secrecy will be lifted.
By Guest Writer David Kliff, Publisher, Diabetic Investor: Although it has taken much longer than I anticipated, market dynamics are forcing companies to think differently and we are now on the verge of patients being prescribed diabetes management systems rather than individual pieces of the system.Read More »
Once given FDA approval, the Senseonics Eversence System will be the fourth CGMS available in the U.S. It was submitted to the FDA for premarket approval last October, supported by data from a 90-patient pivotal trial of the device. The trial followed adults with type 1 or type 2 diabetes over 90 days of CGM sensor wearing. This is an implantable CGM system that is currently approved in Europe. The sensor sits just under your skin and can stay there for anywhere from 90-180 days.Read More »
CGM will be available at lower price, without fingerstick calibration, and can be worn for 10 days with 12-hour warmup.Read More »
Sensor-augmented therapy can diminish hypoglycemia with the low-glucose suspend feature.Read More »
First Continuous Glucose Monitor that doesn’t require routine finger pricks.Read More »